Monopar TherapeuticsMNPR.OValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Fair Value Range” zone.
As of Oct 16, 2026, Monopar Therapeutics (MNPR.O) trades at a negative P/E (-26.06x, due to a recent net loss), P/B of 3.56x, P/S of N/A, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data); P/B sits at the 58th percentile over the trailing 10Y window (vs. 52nd percentile over 3Y); P/S historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data).
Cross-sectional valuation: its P/B ranks at the 66th percentile within its industry and the 75th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 7.53%, ranking at the 94th percentile over the trailing 20Y window.
Relative to industry peers, its P/B shows a deeper discount than it does against the broader market. Shareholder returns here lean heavily on buybacks rather than cash dividends. Monopar Therapeutics operates in the Manufacturing sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: NASDAQ: MNPR · MNPR
Want the full picture on whether Monopar Therapeutics (MNPR.O) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | -26.06 | Negative | Negative | Negative | Negative | Negative | Negative |
| P/B (MRQ) | 3.56 | ||||||
| P/S (TTM) | N/A | — | — | — | — | — | — |
| Dividend Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback + Div Yield | 7.53% |